All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

(2014) Mark S. Sulkowski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors

(2013) Dennis Hernandez et al.   JOURNAL OF CLINICAL VIROLOGY

Treatment of hepatitis C virus genotype 3-infection

(2013) Stanislas Pol et al.   LIVER INTERNATIONAL

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

(2013) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

(2013) Min Gao   Current Opinion in Virology

The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C

(2013) Jeffrey McCombs et al.   JAMA Internal Medicine

In VitroActivity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A

(2012) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

(2011) G. Nkontchou et al.   JOURNAL OF VIRAL HEPATITIS

The global health burden of hepatitis C virus infection

(2011) Francesco Negro et al.   LIVER INTERNATIONAL

Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France

(2010) Christine Larsen et al.   JOURNAL OF MEDICAL VIROLOGY

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C

(2009) Pierre-Yves Bochud et al.   JOURNAL OF HEPATOLOGY